Pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mTOR inhibitors
There is provided a compound of formula I: or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula 1, and the use of a compound of Formula 1 as a medicament and in the treatment of cancer.
1. A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
X 8 is N,
X 5 and X 6 are CH;
R 7 is
and
R 2 is
2. The compound according to claim 1 wherein the compound is a compound of formula Ib:
or a pharmaceutically acceptable salt thereof.
3. The compound according to claim 1 wherein the compound is a compound of formula Ia:
or a pharmaceutically acceptable salt thereof.
4. A pharmaceutical composition comprising a compound according to claim 3 , and a pharmaceutically acceptable carrier or diluent.
5. A method for producing a mTOR inhibitory effect in a warm-blooded animal in need thereof which comprises administering to said animal an effective amount of a compound according to claim 3 , or a pharmaceutically acceptable salt thereof.
6. A compound which is:
or a pharmaceutically acceptable salt thereof.
7. The compound of claim 6 which is:
8. A pharmaceutically acceptable salt of the compound of claim 6 .
9. A pharmaceutical composition comprising a compound according to claim 6 , or a pharmaceutically acceptable salt thereof , and a pharmaceutically acceptable carrier or diluent.